PATENT CLAIM ANALYSIS

Application Number: 16045989
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["514", "001400"]

Abstract:
Methods for treating inflammation include administering to a mammal in need thereof an effective amount of a treatment composition comprising a cyclized compound of the amino acid sequence of formula I: X 1 -GQRETPEGAEAKPWY-X 2   (I) where X 1  includes an amino acid sequence with 1 to 4 members having one or more natural or unnatural amino acids selected from: C, KSP, K, ornithin, 4-amino butanoic acid, β-alanine, 6-amino-hexanoic acid, and 7-amino-heptanoic acid; where X 2  is one natural amino acid selected from: C, D, G and E; and where prior to cyclization, X 1  is the N-terminus and X 2  is the C-terminus.

Claim (Index 11):
A method for treating inflammation, comprising:\n administering, via inhalation, to a mammal in need thereof, an effective amount of a treatment composition comprising one or more of: a cyclic peptide of the amino acid sequence of SEQ ID NO: 1, cyclo (CGQRETPEGAEAKPWYC), wherein both terminal cysteine residues form a disulphide bridge; a cyclic peptide of the amino acid sequence of SEQ ID NO: 2, cyclo (KSPGQRETPEGAEAKPWYE), wherein an amide bond is formed between the amino group attached to the \u03b5-carbon atom of the N-terminal lysine residue and the side chain carboxyl group attached to the \u03b3-carbon of the C-terminal glutamic acid residue; a cyclic peptide of the amino acid sequence of SEQ ID NO: 3, cyclo (KGQRETPEGAEAKPWYG), wherein an amide bond is formed between the amino group attached to the \u03b5-carbon atom of the side chain of the N-terminal lysine residue and the carboxyl group of the C-terminal glycine residue; a cyclic peptide of the amino acid sequence of SEQ ID NO: 4, cyclo (ornithine-GQRETPEGAEAKPWYG), wherein an amide bond is formed between the amino group attached to the \u03b4-carbon of the side chain of the N-terminal ornithine residue and the carboxyl group of the C-terminal glycine residue; a cyclic peptide of the amino acid sequence of SEQ ID NO: 5, cyclo (4-aminobutanoic\u2003acid-GQRETPEGAEAKPWYD), wherein an amide bond is formed between the amino group of the N-terminal 4-aminobutanoic acid residue and the side chain carboxyl group attached to the \u03b2-carbon of the C-terminal aspartic acid residue; a cyclic peptide of the amino acid sequence of SEQ ID NO: 6, cyclo (\u03b2-alanine-GQRETPEGAEAKPWYE), wherein an amide bond is formed between the amino group of the N-terminal \u03b2-alanine (3-aminopropanoic acid) residue and the side chain carboxyl group attached to the \u03b3-carbon of the C-terminal glutamic acid residue; a cyclic peptide of the amino acid sequence of SEQ ID NO: 7, {[7-amino-heptanoic\u2003acid-GQRETPEGAEAKPWY]( cyclo   1-16)}, wherein the amino acids are peptidically linked from the C-terminal amino acid tyrosine to the N-terminal amino acid glycine, the C-terminal amino acid tyrosine being linked to the N-terminal amino acid glycine via an amide bond between the nitrogen of the amino group of the N-terminal glycine and the C1 carbon of the carboxyl group of the 7-amino-heptanoic acid, on the one hand, and via an amide bond between the nitrogen of the amino group of the 7-amino-heptanoic acid and the carbon of the carboxyl group of the C-terminal tyrosine, on the other hand, so that the compound has neither an N-terminal amino group, nor a C-terminal carboxyl group; or a cyclic peptide of the amino acid sequence of SEQ ID NO: 8, {[6-amino-hexanoic\u2003acid-GQRETPEGAEAKPWYG]( cyclo   1-17)}, wherein the amino acids are peptidically linked from the C-terminal amino acid glycine to the N-terminal amino acid glycine, the C-terminal amino acid glycine being linked to the N-terminal amino acid glycine via an amide bond between the nitrogen of the amino group of the N-terminal glycine and the C1 carbon of the carboxyl group of the 6-amino-hexanoic acid, on the one hand, and via an amide bond between the nitrogen of the amino group of the 6-amino-hexanoic acid and the carbon of the carboxyl group of the C-terminal glycine, on the other hand, so that the compound has neither an N-terminal amino group, nor a C-terminal carboxyl group.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.76812
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14372629', '14628644', '12666229', '14326710', '14622177']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7379381724481874
- 35 USC 102 Novelty (BERT): 0.494578610930351
- Combined Prediction Score: 0.7136022162964037
- Mean Citation Score: 192.381272
- Max Citation Score: 204.6925
- Similarity Product: 139.6669087997079

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test